<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Styczyński J</dc:creator>
  <dc:creator>Tridello G</dc:creator>
  <dc:creator>Koster L</dc:creator>
  <dc:creator>Iacobelli S</dc:creator>
  <dc:creator>van Biezen A</dc:creator>
  <dc:creator>van der Werf S</dc:creator>
  <dc:creator>Mikulska M</dc:creator>
  <dc:creator>Gil L</dc:creator>
  <dc:creator>Cordonnier C</dc:creator>
  <dc:creator>Ljungman P</dc:creator>
  <dc:creator>Averbuch D</dc:creator>
  <dc:creator>Cesaro S</dc:creator>
  <dc:creator>de la Camara R</dc:creator>
  <dc:creator>Baldomero H</dc:creator>
  <dc:creator>Bader P</dc:creator>
  <dc:creator>Basak G</dc:creator>
  <dc:creator>Bonini C</dc:creator>
  <dc:creator>Duarte R</dc:creator>
  <dc:creator>Dufour C</dc:creator>
  <dc:creator>Kuball J</dc:creator>
  <dc:creator>Lankester A</dc:creator>
  <dc:creator>Montoto S</dc:creator>
  <dc:creator>Nagler A</dc:creator>
  <dc:creator>Snowden JA</dc:creator>
  <dc:creator>Kröger N</dc:creator>
  <dc:creator>Mohty M</dc:creator>
  <dc:creator>Gratwohl A</dc:creator>
  <dc:date>2020</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Information on incidence, and factors associated with mortality is a prerequisite to improve outcome after hematopoietic stem cell transplantation (HSCT). Therefore, 55'668 deaths in 114'491 patients with HSCT (83.7% allogeneic) for leukemia were investigated in a landmark analysis for causes of death at day 30 (very early), day 100 (early), at 1 year (intermediate) and at 5 years (late). Mortality from all causes decreased from cohort 1 (1980-2001) to cohort 2 (2002-2015) in all post-transplant phases after autologous HSCT. After allogeneic HSCT, mortality from infections, GVHD, and toxicity decreased up to 1 year, increased at 5 years; deaths from relapse increased in all post-transplant phases. Infections of unknown origin were the main cause of infectious deaths. Lethal bacterial and fungal infections decreased from cohort 1 to cohort 2, not unknown or mixed infections. Infectious deaths were associated with patient-, disease-, donor type, stem cell source, center, and country- related factors. Their impact varied over the post-transplant phases. Transplant centres have successfully managed to reduce death after HSCT in the early and intermediate post-transplant phases, and have identified risk factors. Late post-transplant care could be improved by focus on groups at risk and better identification of infections of "unknown origin".</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.ch/global/documents/92776</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1038/s41409-019-0624-z</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/31455899</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>Bone marrow transplantation. - 2020</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Transplantation</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Hematology</dc:subject>
  <dc:title xmlns:ns3="xml" ns3:lang="en">Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
